Icotinib
- Generic Name
- Icotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N3O4
- CAS Number
- 610798-31-7
- Unique Ingredient Identifier
- 9G6U5L461Q
- Background
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
...
- Indication
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
- Associated Conditions
- -
- Associated Therapies
- -
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2019-01-30
- Target Recruit Count
- 66
- Registration Number
- NCT03766490
- Locations
- 🇨🇳
The First Affiliated hospital of soochow university, Suzhou, Jangsu, China
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT03754530
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03749213
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, China
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03396185
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, China
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03349203
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, China
Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03346811
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Beijing, Beijing, China
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03153358
Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 118
- Registration Number
- NCT03151161
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02961270
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT02960607
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.